aTyr Pharma, Inc. — 2016 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2016, filed March 16, 2017. aTyr is a clinical-stage biotechnology company developing protein therapeutics based on its Physiocrine biology platform. It reported no product revenue and operated as one business segment.
Its pipeline comprised Resolaris, in Phase 1b/2 studies for rare muscular diseases; Stalaris, a potential treatment for rare pulmonary diseases with an immune component, with Phase 1 planned for the second half of 2017; and Project ORCA, in preclinical research.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $42.8 million | $34.5 million |
| General and administrative expense | $15.1 million | $13.1 million |
| Operating loss | $57.9 million | $47.6 million |
| Net loss | $57.9 million | $48.0 million |
| Net loss per share, basic and diluted | $2.44 | $3.03 |
| Net cash used in operating activities | $52.9 million | $36.8 million |
Gross margin is not meaningful because the company had no product sales. R&D expense rose $8.3 million, principally from Resolaris development, Stalaris manufacturing development, other preclinical work, Resolaris manufacturing, and increased R&D staffing.
At year-end, cash, cash equivalents and available-for-sale investments totaled $76.1 million, down from $125.3 million a year earlier. Working capital was $66.2 million; total assets were $80.5 million. The company reported $9.5 million of debt carrying value, including $0.3 million current and $9.2 million long-term. It said existing cash and investments were expected to fund operations for at least one year from the filing date.
Operating cash use increased by $16.1 million year over year. Investing activities provided $33.5 million, largely from investment maturities; financing activities provided $4.7 million, including net proceeds from the new term loan. The company reported an accumulated deficit of $216.0 million.
Material changes versus the prior comparable period
- Net loss increased by $9.9 million, from $48.0 million to $57.9 million; operating expenses increased by $10.3 million.
- Operating cash use increased to $52.9 million from $36.8 million.
- Cash and investments declined by $49.2 million from year-end 2015.
- In November 2016, aTyr borrowed $10 million under a term loan, repaid its prior Silicon Valley Bank loan, and had up to another $10 million available subject to milestones. The loan is variable-rate, secured by substantially all assets other than intellectual property, and matures in November 2020.
Outlook, commentary, risks and unusual items
- Management expected continuing losses and higher expenses as Resolaris development continued, Stalaris advanced, and research and manufacturing programs expanded. The company stated it would need substantial additional funding to complete pivotal trials and pursue commercialization; financing or partnerships could dilute shareholders or require giving up product rights.
- Resolaris was generally described as well tolerated across 44 patients and 24 healthy volunteers, with no investigator-reported serious adverse events as of year-end. Mild-to-moderate adverse events, infusion reactions, and protocol discontinuations were reported. Low anti-drug-antibody signals were observed but had not triggered neutralizing assays.
- Exploratory efficacy observations included average manual muscle test score increases of 6.2% in LGMD2B patients and 6.7% in the first four early-onset FSHD patients completing treatment. The studies were small and not powered to establish efficacy. In the placebo-controlled adult FSHD study, the 3.0 mg/kg cohort reported a 9.9% improvement in INQoL versus a 15.6% worsening for placebo at week 14.
- Management expected to report early-onset FSHD study results in the second quarter of 2017 and planned to begin Stalaris Phase 1 testing in the second half of 2017. These are forward-looking plans, not assurances of outcomes or timing.
- Key risks include clinical and regulatory uncertainty, limited rare-disease patient pools, reliance on third-party manufacturers and clinical organizations, need for additional capital, variable-rate and covenant-bearing debt, and potential safety or immunogenicity issues. aTyr also disclosed trademark objections from Alexion concerning Resolaris and from Novartis concerning Stalaris and Resolaris; it was assessing its response.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. The independent auditor issued an unqualified opinion on the financial statements. Management judged disclosure controls and internal control over financial reporting effective; the auditor did not provide an ICFR attestation under the emerging-growth-company transition relief.
Important facts for investors to verify
- Whether subsequent controlled clinical data validate the exploratory Resolaris findings and clarify safety, infusion reactions, and antibody signals.
- Actual timing, design, enrollment, and results of the planned Resolaris and Stalaris trials, including whether Stalaris entered Phase 1 as expected.
- Cash burn, runway, and the conditions for drawing the remaining $10 million under the term loan; assess financing needs and potential dilution.
- Manufacturing readiness, costs, and supply continuity for Resolaris and Stalaris, including milestone commitments to contract manufacturers.
- Status and outcome of the Resolaris and Stalaris trademark disputes, and any resulting rebranding costs or commercial implications.